• Drugs
  • Thursday, 01 Feb 2024

Parenteral Nutrition Market is expected to reach US$ 11.12 billion by 2030

Publisher: The Insight Partners

Single Dose Amino Acid Solution Segment to Hold Significant Share of Parenteral Nutrition Market During 2022–2030

According to our latest study on "Parenteral Nutrition Market Forecast to 2030 – Global Analysis – by Nutrient Type, and End User," the parenteral nutrition market size was valued at US$ 6.84 billion in 2022 and is expected to reach US$ 11.12 billion by 2030. The market is estimated to register a CAGR of 6.0% from 2022 to 2030.

The rise in the prevalence of gastrointestinal diseases and the surge in cases of malnutrition and premature births are the key factors fueling the market progress. However, mechanical, gastrointestinal, and metabolic complications associated with parenteral feeding systems hinder the parenteral nutrition market growth.

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00005217

The parenteral nutrition market trends include innovation in the formulations of nutrition products. There is a surge in the demand for products that help consumers proactively manage their health, especially those focused on specific needs in terms of energy levels, immunity, and disease treatment. Nutritional requirements differ based on the type of illness. Functionality and specific formulations of the parenteral products do not interfere with the existing treatment provided to patients and help deliver a more precise and enhanced treatment as per the requirement. The macronutrient and micronutrient formulations of parenteral nutrition and their applications vary based on the type of disease, including cancer and gastrointestinal diseases.

Significant developments in innovative formulations bring in a new era of nutritional solutions that are designed to meet all individual demands as well as the medical conditions of each patient. This level of personalization improves patient outcomes in addition to increasing the effectiveness of parenteral nutrition. Formulation innovations enable the market to fully meet the unique nutritional needs of different patients, from newborns and older adults to people with certain medical conditions. For example, the emergence of lipid-based emulsions with improved stability and bioavailability is changing the face of intravenous nourishment, especially for the treatment of premature infants. Additionally, the inherent risks of problems and side effects that have traditionally been connected to conventional nutritional solutions are reduced because of these formulation innovations.  The industry is positioned for exceptional growth and long-term success because of its dual benefits of promoting the adoption of parenteral nutrition within the healthcare ecosystem and improving patient care.

Parenteral Nutrition Market, by Nutrient Type

The parenteral nutrition market, by nutrient type, is segmented into carbohydrates, parenteral lipid emulsion, single dose amino acid solution, trace elements, and vitamins and minerals. The parenteral nutrition market analysis estimated that the single dose amino acid solution segment held the largest share of the market in 2022, and the parenteral lipid emulsion segment is likely to register the highest CAGR in the parenteral nutrition market during 2022–2030. There is a growing need for nutrition therapies such as parenteral amino acids that deliver a substantial amount of protein, but not a toxic amount of energy, to slow down protein catabolism in critically ill patients. Amino acid supplementation is given to patients in case of insufficient amino acid intake in healthy individuals and specific physiological or pathophysiological situations. The amino acid requirement is lower in parenterally-fed infants and children than in enterally-fed infants because the supply bypasses the intestine.  

In terms of end user, the market is categorized into hospitals, clinics, and others. The hospitals segment is anticipated to hold a significant parenteral nutrition market share by 2030; however, the clinic segment is likely to register the highest CAGR in the parenteral nutrition market during 2022–2030. Hospitals are considered the largest entities that have all the facilities available. Hospitals also provide various diagnostics and treatment facilities that can be reimbursed under insurance claims. Hospitals are associated with various doctors, specialists’ doctors, and other professionals who provide enhanced healthcare services. All types of cardiovascular diseases can be treated in hospitals. Hospitals serve a substantial role by providing extensive medical services, including nursing services, to patients suffering from a variety of diseases. This increased the adoption of transdermal drug delivery systems for several diseases and surgeries among patients in hospitals.

Parenteral Nutrition Market, by Geography:

The scope of the parenteral nutrition market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

In 2022, in terms of revenue, North America dominated the parenteral nutrition market share. The US holds the largest market share in the region. Cancer, heart disease, and other chronic diseases are the major causes of disability and death in the US. Per the National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 people in the country are diagnosed with at least one chronic disease. Additionally, the American Hospital Association estimates that ~133 million people have at least one chronic disease, and that number is expected to reach 170 million by 2030. According to an article titled “Trends in Parenteral Nutrition,” published in January 2019; on average, ~34,000 patients receive parenteral nutrition (PN) annually in the US. Enteral tube feeding can be prescribed for treating more than 350 diseases and medical conditions in children. The US parenteral nutrition market growth is further fueled by government initiatives to make people aware of enteral and parenteral nutrition through awareness programs. For instance, the Feeding Tube Awareness Foundation creates awareness about the adoption of feeding tubes as a lifesaving medical intervention and helps parents of tube-fed children. The foundation celebrated the annual Feeding Tube Awareness Week from February 4, 2019, to February 8, 2019.

The parenteral nutrition market report is focused on prominent players in the market such as ICU Medical Inc, Grifols SA, Pfizer Inc, Otsuka Pharmaceuticals Co Ltd, Baxter International Inc, B Braun SE, Fresenius Kabi AG, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, Vifor Pharma Management AG, and Aculife Healthcare Pvt Ltd. The parenteral nutrition market forecast can help stakeholders plan their growth strategies. These companies focus on new technologies, upgrading existing products, and geographic expansions to meet the rising consumer demand worldwide. 

  • In December 2022, Baxter International Inc introduced the ExactaMix Pro Automated Compounder in the US. The product debuted in the beginning of 2023. The recently released product makes use of cutting-edge compounding technology to enhance patient safety, process effectiveness, and formulation accuracy.
  • In October 2022, B. Braun SE demonstrated its macro and micro compounder, APEX Compounding System, and its proprietary TPN Manager Clinical Decision Support Order Entry Software. In order to reduce the chance of precipitation, the TPN Manager program included Trissel's Ca/P check, which enables users to create templates to standardize their order format.

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com


Related News